Joint pain injections market to reach $10.96 billion by 2030

The Business Research Company says the global joint pain injections market is on track to grow from $6.12 billion in 2025 to $10.96 billion by 2030, driven by rising arthritis cases, aging populations and demand for non-surgical pain relief. North America held the largest share in 2025 and is expected to stay in front as biologic and regenerative treatments gain traction.

Why it matters: - Joint pain injections are moving from a niche treatment to a larger part of pain management as arthritis and other musculoskeletal disorders rise worldwide. - The market’s projected jump to $10.96 billion by 2030 signals more demand for outpatient, minimally invasive and non-opioid treatment options. - Growth in biologics, hyaluronic acid and platelet-rich plasma injections could reshape how clinicians treat joint pain.

What happened: - The Business Research Company released a report on the global joint pain injections market, with a 2026 edition covering market size, trends and forecasts through 2035. - The market is estimated at $6.12 billion in 2025 and projected to reach $6.89 billion in 2026. - The report forecasts the market will grow to $10.96 billion by 2030, implying a 12.3% CAGR over the forecast period. - North America held the largest market share in 2025.

The details: - Joint pain injections deliver medication directly into an affected joint to reduce inflammation and discomfort. - The approach offers rapid relief without surgery and is widely used as a non-surgical pain management option. - Key historical growth drivers include rising arthritis and joint disorder cases, an aging global population, greater awareness of regenerative treatments and expansion of orthopedic specialty care. - Future growth is expected to come from broader use of biologic pain therapies, personalized medicine, sports injury treatment, regenerative medicine investment and preference for non-opioid pain relief. - Emerging trends include more non-surgical pain management, increased use of hyaluronic acid and platelet-rich plasma injections, and stronger demand for outpatient-friendly options. - The report includes regional analysis for Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, total addressable market analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast reflects a broader shift toward treatments that avoid surgery and opioids, especially as older adults and patients with chronic joint disease seek faster relief. - The inclusion of regenerative medicine and personalized treatment signals that the market is evolving beyond traditional steroid-style pain control. - IHME projected in August 2023 that nearly 1 billion people will have osteoarthritis by 2050, underscoring the scale of future demand. - The report’s regional split suggests North America remains the most mature market, while other regions may be earlier in adoption but expanding with healthcare infrastructure.

What's next: - The Business Research Company expects the market to keep compounding through 2030 as biologic and regenerative injection therapies gain wider use. - Wider outpatient adoption and stronger interest in non-opioid care could support additional growth beyond the near term. - More regional competition may emerge as healthcare access and pain-management awareness improve outside North America.

The bottom line: - Joint pain injections are becoming a bigger global market because patients and providers want treatments that are faster, less invasive and easier to deliver outside the operating room.